A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS

Inclusion Criteria: * The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol. * In accordance with regional/local laws and regulations, * a. the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has * b.given written assent, if applicable, to participate in the study (for participants between 7 to 12 years) * Age: Participant must be aged greater than or equal to (\>=) 3 months to 12 years, of either gender. * Participants who are otherwise healthy and presenting with suspected CAP. * For participants clinically suspected of CAP, at least 3 of the following 4 criteria are applicable: * a) History of productive cough and/or shortness of breath. * b)Fever greater than (\>)38.5 degree Celsius (○C) (Axillary temperature) * c) Tachypnea as defined by Respiratory rate (RR) \>= 50 breaths/minute in children up to 11 months RR \>= 40 breaths/minute in children from 12 months onwards * d) Chest X-Ray with shadow or lobar condensation, unilateral or bilateral. For participants of ABRS: * The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol. * In accordance with regional/local laws and regulations, * a..The parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has * b. given written assent, if applicable, to participate in the study (for participants between 7 to 12 years). * Age: Participant must be between \>=3 months to 12 years of either gender. * Participants who are otherwise healthy and presenting with suspected ABRS. * For participants of clinically suspected ABRS, the participants would be eligible if any of the following 2 of the 3 criteria stated below are met: * a.Children with purulent nasal discharge or daytime productive cough (which may worsen at night) or both persisting for 10 days or more without evidence of improvement. * b. Fever \> 38.3○C (Axillary temperature) * c. Double sickness defined as initial improvement of symptoms and further worsening/ deterioration after 5 days. Exclusion Criteria: * Severe ABRS/CAP requiring hospitalization. * Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study. * A serious underlying disease as per clinician's judgment. * Human immunodeficiency virus (HIV) infection/or any other immunosuppressive condition * Pre-existing renal insufficiency (for example \[e.g.\], plasma creatinine \> 1.5 times upper limit of normal range for age). * Pre-existing liver disease(s) and/or hepatic dysfunction. * Any pre-existing malignancy/any participants undergoing any kind of chemotherapy. * Evidence of leukopenia and/or thrombocytopenia. * History of previous hypersensitivity reaction to penicillins, cephalosporins or other Beta-lactam antibiotics. * History of amoxicillin-clavulanate associated cholestatic jaundice/hepatic dysfunction. * History of phenylketonuria or a known hypersensitivity to aspartame. * Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function. * Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter renal function like probenecid. * Participants who have chronic sinusitis (signs and symptoms lasting greater than 28 days prior to screening visit. * Significant abnormalities of the sinuses and any complications of ABRS. * Have concurrent streptococcal pharyngitis or acute otitis media (as the standard doses for both of these conditions is 10 days). * Any other infection or condition, which necessitates use of a concomitant systemic antimicrobial. * History of infectious mononucleosis. * History of pseudomembranous colitis. * Participants that are on warfarin therapy. * Receipt of an investigational compound (non-food and drug administration \[FDA\] and non-Brazil National Health Surveillance Agency \[ANVISA\] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study. * Participants with symptoms suggestive of active Coronavirus disease 2019 (COVID-19) infection (that is (i.e.), fever, cough, etc.) * Participants with known COVID-19 positive contacts within the past 14 days. * Female participants who have attained menarche